Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Fiche du document
- doi: 10.1016/j.esmoop.2022.100446
- issn: 2059-7029
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.esmoop.2022.100446
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35427834
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2059-7029
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_FA0FF9C4B3E94
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Mesothelium--TumorsCiter ce document
M. Mark et al., « Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. », Serveur académique Lausannois, ID : 10.1016/j.esmoop.2022.100446
Métriques
Partage / Export
Résumé
The SAKK 17/16 study showed promising efficacy data with lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma. Here, we evaluated long-term outcome and analyzed the impact of lurbinectedin monotherapy on the tumor microenvironment at the cellular and molecular level to predict outcomes. Forty-two patients were treated with lurbinectedin in this single-arm study. Twenty-nine samples were available at baseline, and seven additional matched samples at day one of cycle two of treatment. Survival curves and rates between groups were compared using the log-rank test and Kaplan-Meier method. Statistical significance was set at P value